Clinical trial of drug wesnil plus to see its safety and efficacy in alcohol deaddiction treatment

AProspective open lable clinical study to assess the safety and efficacy of Wesnil Plus in alcohol deaddiction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/09/045406

Enrollment

Registered

2022-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Chronic alcohol drinking history more than 3 years. Alcohol withdrawal patients, including vomiting, nausea, tremors, anxiety, agitation etc. that had presented at that time.

Exclusion criteria

Exclusion criteria: Nervous, Cardio, Vascular, Renal, Metabolic, etc. - patients with h/o haematemisis, active PR bleeding and hoemorrhoids - Patient who has clinical history of sensitivity of ingredients contains in Wesnil Plus. - Patient suffering from uncontrolled DM, HTN , Acute coronary Artery diseases, Asthma & any other major illness. - Patients on antitubercular and antiretroviral treatment. - Patient whose heart, liver or kidney function is seriously abnormal. - Patient who has participated in other clinical trial within two months before starting these trials.

Design outcomes

Primary

Measure	Time frame
Mean reduction (Mean Ã?Â± SD) in desire and frequency of alcohol consumption.Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Global assessment score for the accessibility of Wesnil Plus. Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDrRajeshwar Reddy

R A Podar govt.medical college (Ayu) Worli

reddyrajeshwar@rediffmail.com9820864287

Outcome results